File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation

TitlePreemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation
Authors
Issue Date2002
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 2002, v. 36 n. 3, p. 702-709 How to Cite?
AbstractExacerbation of hepatitis B virus (HBV) is a serious cause of morbidity and mortality in hepatitis B surface antigen (HBsAg)-positive patients undergoing transplantation. Our aim was to evaluate the effectiveness of lamivudine to prevent hepatitis due to exacerbation of HBV in HBsAg-positive patients treated with allogeneic hematopoietic cell transplantation. We studied 20 consecutive HBsAg-positive recipients of allogeneic hematopoietic cell transplantation who received lamivudine 100 mg daily starting one week before transplantation until week 52 after transplantation (group 1). Serial serum alanine aminotransferase and HBV DNA levels were measured before and after transplantation at 4- to 8-week intervals for the first year and then 4- to 12-week intervals. Their virologic and clinical outcomes were compared with 20 case-matched recipients who did not receive any antiviral therapy to HBV (anti-HBV) before and after hematopoietic cell transplantation (group 2). After transplantation, 9 patients (45%) in group 2 and one patient (5%) in group 1 had hepatitis due to exacerbation of HBV (P < .008), with 3 hepatic failures in group 2 and none in group 1. The one-year actuarial probability of survival without hepatitis due to exacerbation of HBV was higher in group 1 than group 2 (94.1% vs. 54.3%, P = .002). By multivariate Cox analysis, preemptive use of lamivudine effectively reduced hepatitis due to exacerbation of HBV (adjusted hazards ratio, 0.09; P = .021). In conclusion, preemptive lamivudine reduced HBV exacerbation. The use of lamivudine with other immunosuppressive regimens to prevent exacerbation of HBV should be further explored.
Persistent Identifierhttp://hdl.handle.net/10722/87576
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLau, GKKen_HK
dc.contributor.authorHe, MLen_HK
dc.contributor.authorFong, DYTen_HK
dc.contributor.authorBartholomeusz, Aen_HK
dc.contributor.authorAu, WYen_HK
dc.contributor.authorLie, AKWen_HK
dc.contributor.authorLocarnini, Sen_HK
dc.contributor.authorLiang, Ren_HK
dc.date.accessioned2010-09-06T09:31:38Z-
dc.date.available2010-09-06T09:31:38Z-
dc.date.issued2002en_HK
dc.identifier.citationHepatology, 2002, v. 36 n. 3, p. 702-709en_HK
dc.identifier.issn0270-9139en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87576-
dc.description.abstractExacerbation of hepatitis B virus (HBV) is a serious cause of morbidity and mortality in hepatitis B surface antigen (HBsAg)-positive patients undergoing transplantation. Our aim was to evaluate the effectiveness of lamivudine to prevent hepatitis due to exacerbation of HBV in HBsAg-positive patients treated with allogeneic hematopoietic cell transplantation. We studied 20 consecutive HBsAg-positive recipients of allogeneic hematopoietic cell transplantation who received lamivudine 100 mg daily starting one week before transplantation until week 52 after transplantation (group 1). Serial serum alanine aminotransferase and HBV DNA levels were measured before and after transplantation at 4- to 8-week intervals for the first year and then 4- to 12-week intervals. Their virologic and clinical outcomes were compared with 20 case-matched recipients who did not receive any antiviral therapy to HBV (anti-HBV) before and after hematopoietic cell transplantation (group 2). After transplantation, 9 patients (45%) in group 2 and one patient (5%) in group 1 had hepatitis due to exacerbation of HBV (P < .008), with 3 hepatic failures in group 2 and none in group 1. The one-year actuarial probability of survival without hepatitis due to exacerbation of HBV was higher in group 1 than group 2 (94.1% vs. 54.3%, P = .002). By multivariate Cox analysis, preemptive use of lamivudine effectively reduced hepatitis due to exacerbation of HBV (adjusted hazards ratio, 0.09; P = .021). In conclusion, preemptive lamivudine reduced HBV exacerbation. The use of lamivudine with other immunosuppressive regimens to prevent exacerbation of HBV should be further explored.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_HK
dc.relation.ispartofHepatologyen_HK
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.en_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHematopoietic Stem Cell Transplantationen_HK
dc.subject.meshHepatitis B Surface Antigens - analysisen_HK
dc.subject.meshHepatitis B virus - isolation & purificationen_HK
dc.subject.meshHepatitis B, Chronic - drug therapy - mortality - prevention & controlen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLamivudine - administration & dosageen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshProportional Hazards Modelsen_HK
dc.subject.meshReverse Transcriptase Inhibitors - administration & dosageen_HK
dc.subject.meshSurvival Analysisen_HK
dc.subject.meshTransplantation, Homologousen_HK
dc.titlePreemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0270-9139&volume=36 &issue=3&spage=702&epage=9&date=2002&atitle=Preemptive+Use+of+Lamivudine+Reduces+Hepatitis+B+Exacerbation+After+Allogeneic+Hematopoietic+Cell+Transplantationen_HK
dc.identifier.emailFong, DYT: dytfong@hku.hken_HK
dc.identifier.emailLiang, R: rliang@hku.hken_HK
dc.identifier.authorityFong, DYT=rp00253en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1053/jhep.2002.35068en_HK
dc.identifier.pmid12198664-
dc.identifier.scopuseid_2-s2.0-0036730423en_HK
dc.identifier.hkuros75581en_HK
dc.identifier.hkuros77676-
dc.identifier.hkuros83501-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036730423&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume36en_HK
dc.identifier.issue3en_HK
dc.identifier.spage702en_HK
dc.identifier.epage709en_HK
dc.identifier.isiWOS:000177722500022-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLau, GKK=7102301257en_HK
dc.identifier.scopusauthoridHe, ML=35080389700en_HK
dc.identifier.scopusauthoridFong, DYT=35261710300en_HK
dc.identifier.scopusauthoridBartholomeusz, A=6701915061en_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridLie, AKW=7004510870en_HK
dc.identifier.scopusauthoridLocarnini, S=35953095500en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats